CBAN
Colony Bankcorp, Inc.
CBAN offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
MS
Morgan Stanley
MS has a slight edge over CBAN overall, supported by stronger modeled upside and stronger fundamentals.
CBAN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CBAN's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CBAN.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CBAN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $20.30 | — |
| Cheap | 9.4x | $17.14 | -16% |
| Fair | 11x | $20.26 | -0.2% |
| Current | 11x | $20.30 | — |
| Expensive | 13x | $22.83 | +12% |
Historical ranges are pointers, not guarantees.
CBAN has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
CBAN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CBAN, but weaker profitability.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over CBAN on the outlook, with more favorable profitability expectations.
CBAN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.28 | +25% |
| Q3 2026 | $1.82 | +14% |
| Q2 2026 | $1.65 | +3.8% |
| Q1 2026 | $1.60 | +11% |
| Q4 2025 | $1.59 | +17% |
| Q3 2025 | $1.60 | +28% |
| Q2 2025 | $1.59 | +26% |
| Q1 2025 | $1.44 | +15% |
| Q4 2024 | $1.36 | +9.7% |
CBAN's earnings per share have climbed steadily: $1.82 over the past year, up 14% from the year before, and higher year over year for 13 quarters in a row.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CBAN on earnings, with stronger typical year-over-year growth.
CBAN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.6M | +30% |
| Q2 2026 | $42M | +29% |
| Q1 2026 | $39.9M | +33% |
| Q4 2025 | $36.9M | +20% |
| Q3 2025 | $32.8M | +15% |
| Q2 2025 | $32.5M | +16% |
| Q1 2025 | $30M | +6.6% |
| Q4 2024 | $30.8M | +9.2% |
CBAN has the edge over MS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +9.1 points |
| Q2 2026 | 33% | +1.7 points |
| Q1 2026 | 26% | -1.3 points |
| Q4 2025 | 26% | -2.9 points |
| Q3 2025 | 22% | -2.4 points |
| Q2 2025 | 31% | +6.1 points |
| Q1 2025 | 28% | +3.6 points |
| Q4 2024 | 29% | +3.6 points |
CBAN's operating margin was 31% last quarter, up 9.1 points from the same quarter a year ago, near the top of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over CBAN on profitability, with a higher operating margin.
CBAN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | -67% |
| Q2 2026 | $8.2M | -48% |
| Q1 2026 | $53.8M | +206% |
| Q4 2025 | -$54.3M | -$50.5M |
| Q3 2025 | $14.1M | -30% |
| Q2 2025 | $15.8M | +1492% |
| Q1 2025 | $17.6M | +257% |
| Q4 2024 | -$3.8M | -174% |
CBAN has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CBAN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +60.6K shares |
| 1 year | +22% | +3.8M shares |
| 3 years | +21% | +3.7M shares |
| 5 years | +123% | +11.7M shares |
| Available history | +132% | +12.1M shares |
CBAN has 21M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $1.8M |
| Q4 2025 | $779,000 |
| Q3 2025 | — |
| Q2 2025 | $959,000 |
| Q1 2025 | $630,000 |
| Q4 2024 | $540,000 |
CBAN spent $3M buying back its own shares over the past year, up 20% from the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over CBAN on shareholder dilution, with a more favorable share count trend.
CBAN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 7.4x | High |
| Q1 2026 | 9.2x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 9.7x | High |
| Q2 2025 | 9.7x | High |
| Q1 2025 | 11.1x | High |
| Q4 2024 | 5.9x | High |
CBAN's net debt is about 8.5 years of its operating earnings (EBITDA), down from 9.7 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CBAN.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS has the edge over CBAN on leverage, with a lower net debt burden relative to earnings.
CBAN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.0 | Neutral |
| Stochastic | 25.3 | Neutral |
CBAN's weekly RSI is 48 (neutral) and its Stochastic is 25 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CBAN PE vs Financial Services Sector
| Metric | CBAN | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 14% below |
| PE % | 50 | 63 | 13 pts below |
CBAN has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
CBAN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.3 | 0.2% above |
| 20 week MA | $20.9 | 2.9% below |
| 50 week MA | $20.1 | 0.9% above |
| 100 week MA | $18.2 | 12% above |
| 200 week MA | $15.1 | 34% above |
CBAN has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CBAN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.5 | $14.1 | -14% |
| 2021 | $14.1 | $16.8 | +19% |
| 2022 | $16.8 | $12.9 | -23% |
| 2023 | $12.9 | $13.3 | +3.1% |
| 2024 | $13.3 | $16.3 | +22% |
| 2025 | $16.3 | $18.1 | +11% |
| 2026 YTD | $18.1 | $20.3 | +12% |
CBAN has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.